QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
NASDAQ:BCLI

Brainstorm Cell Therapeutics - BCLI Stock Forecast, Price & News

$1.60
-0.06 (-3.61%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.57
▼
$1.63
50-Day Range
$1.50
▼
$4.42
52-Week Range
$1.09
▼
$4.70
Volume
51,846 shs
Average Volume
142,047 shs
Market Capitalization
$58.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Brainstorm Cell Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
212.5% Upside
$5.00 Price Target
Short Interest
Bearish
9.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.72) to ($0.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

682nd out of 1,033 stocks

Biological Products, Except Diagnostic Industry

107th out of 170 stocks

See Top Rated MarketRank™ Stocks Here
BCLI stock logo

About Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

November 14, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
November 10, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
November 10, 2022 | finance.yahoo.com
FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis
November 8, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
November 7, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
October 20, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
October 7, 2022 | finance.yahoo.com
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium
October 4, 2022 | finance.yahoo.com
BCLI: Relvyrio™ Approval Shows FDA Flexibility for ALS Treatments…
September 15, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
August 17, 2022 | finance.yahoo.com
BCLI: Filing a BLA for NurOwn® for the Treatment of ALS…
August 15, 2022 | seekingalpha.com
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q2 2022 Results - Earnings Call Transcript
August 15, 2022 | seekingalpha.com
BrainStorm to seek FDA approval for ALS therapy despite Phase 3 setback
August 15, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
August 10, 2022 | americanbankingnews.com
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com
August 1, 2022 | finance.yahoo.com
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
May 31, 2022 | finance.yahoo.com
BrainStorm Announces Presentations at June 2022 Scientific Conferences
May 24, 2022 | finance.yahoo.com
BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…
May 16, 2022 | investing.com
Brainstorm Cell Therapeutics Misses Q1 EPS by 2c
May 16, 2022 | seekingalpha.com
BrainStorm Cell Therapeutics GAAP EPS of -$0.15 misses by $0.02
May 16, 2022 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
May 13, 2022 | benzinga.com
Brainstorm Cell Earnings Preview
May 12, 2022 | finance.yahoo.com
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal
May 4, 2022 | finance.yahoo.com
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
May 3, 2022 | finance.yahoo.com
BrainStorm Announces Upcoming Scientific Conference Presentations
May 2, 2022 | finance.yahoo.com
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Company Calendar

Last Earnings
11/15/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCLI
CUSIP
N/A
CIK
1137883
Web
www.brainstorm-cell.com
Phone
(201) 488-0460
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+212.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,460,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-236.36%
Return on Assets
-116.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.84
Quick Ratio
0.84

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.53 per share
Price / Book
3.02

Miscellaneous

Outstanding Shares
36,486,000
Free Float
28,809,000
Market Cap
$58.38 million
Optionable
Optionable
Beta
-0.44

Key Executives

  • Mr. Chaim Lebovits (Age 51)
    Chief Exec. Officer
    Comp: $1.02M
  • Dr. Irit Arbel DSc (Age 62)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Dr. Ralph Z. Kern (Age 64)
    Pres & Chief Medical Officer
    Comp: $812.86k
  • Dr. Stacy R. Lindborg Ph.D. (Age 51)
    Exec. VP & Chief Devel. Officer
    Comp: $736.68k
  • Mr. Uri Yablonka (Age 45)
    Exec. VP, Chief Bus. Officer, Sec. & Director
  • Ms. Alla Patlis CPA (Age 35)
    M.B.A., Controller & Interim CFO
  • Dr. David Setboun M.B.A. (Age 47)
    Pharm.D., Exec. VP & COO
  • Dr. Yael Gothelf
    VP of Scientific & Regulatory Affairs
  • Ms. Antal Pearl-Lendner
    VP & Chief Legal Counsel
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BCLI Stock - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price forecast for 2023?

1 brokers have issued 12-month price targets for Brainstorm Cell Therapeutics' stock. Their BCLI share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 214.5% from the stock's current price.
View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2022?

Brainstorm Cell Therapeutics' stock was trading at $4.00 on January 1st, 2022. Since then, BCLI shares have decreased by 60.3% and is now trading at $1.59.
View the best growth stocks for 2022 here.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our BCLI earnings forecast.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its earnings results on Monday, November, 15th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. During the same period last year, the business posted ($0.14) earnings per share.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Isoray (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Abner Herrman & Brock LLC (0.77%), Raymond James & Associates (0.67%), Price T Rowe Associates Inc. MD (0.30%), Renaissance Technologies LLC (0.15%), TRU Independence Asset Management 2 LLC (0.12%) and Jmac Enterprises LLC (0.11%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $1.59.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $58.01 million. The biotechnology company earns $-24,460,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.

This page (NASDAQ:BCLI) was last updated on 12/5/2022 by MarketBeat.com Staff